Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Early-July reversal ⢠Lower-high pattern ⢠High-20s support Support Level: $27.4-$27.6 Resistance Level: $28.4-$29.0 TCMD rallied into early July but has since reversed lower, leaving the stock vulnerable unless it can hold the $27.4-$27.6 support zone and reclaim $28.4-$29.0.
Sentiment & News
Key News Insights: ⢠Share volatility ⢠Distribution expansion ⢠Earnings ahead TCMD is balancing stock volatility with expansion via an exclusive U.S. distribution deal for MyoSleeve and an upcoming Q2 fiscal 2026 earnings report that could reset investor sentiment.
AI Summary
TCMD is transitioning from a speculative niche medtech name to a credible operating-leverage story, but the stock likely won't rerate unless the next earnings report confirms that 20%+ growth, 76% gross margins, and new channel/product wins are sustainable despite reimbursement and integration risk.
Description
Tactile Systems Technology, Inc. is a U.S.-based medical device company that produces and markets noninvasive therapies for chronic conditions. Its product portfolio includes pneumatic compression systems for lymphedema and other venous disorders and a portable chest wall oscillation device for managing retained pulmonary secretions. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 19 | Feb 26 | TCMD | Tactile Systems Technology, Inc. | Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics. | Closed | +5.9% |